Researchers at UCLA have pioneered a non-viral gene therapy system, utilizing lipid nanoparticles (LNPs), to deliver the complete cystic fibrosis transmembrane conductance regulator (CFTR) gene into human airway cells. This innovative LNP platform integrates CRISPR/Cas9 technology for precise gene insertion, bypassing the limitations of viral vectors such as immune responses and payload restrictions.
Cystic fibrosis, a condition stemming from CFTR gene mutations, severely impacts airway fluid balance. For patients with mutations resulting in minimal or no CFTR protein, current modulator drugs are ineffective. This new LNP system successfully delivered a functional CFTR gene into laboratory-grown airway cells with a severe G542X mutation. Despite integrating into a small percentage of cells, the therapy restored near-complete chloride channel function across the cell population.
This gene insertion strategy holds promise for a durable, potentially one-time treatment, unlike therapies requiring frequent re-administration. The primary challenge remains effectively targeting long-lived airway stem cells deep within the lung lining. Overcoming this hurdle would ensure a continuous supply of healthy airway epithelium.
The modular LNP system's adaptability extends beyond cystic fibrosis, offering a scalable and potentially more affordable platform for treating other genetic lung disorders caused by large genes. This approach could provide mutation-agnostic treatment options for patients with limited or no current therapeutic avenues.